Enhanced antitumor effects by combination gene therapy using MDR1 gene shRNA and HSV1-tk in a xenograft mouse model

被引：14

作者：

Lee, Sang-Woo ^{[1
]}

La Lee, You ^{[1
]}

Lee, Yong Jin ^{[1
]}

Park, Seung-Yoon ^{[2
]}

Kim, In-San ^{[3
]}

Choi, Tae Hyun ^{[4
]}

Ha, Jeoung-Hee ^{[5
]}

Ahn, Byeong-Cheol ^{[1
]}

Lee, Jaetae ^{[1
]}

机构：

[1] Kyungpook Natl Univ, Dept Nucl Med, Sch Med, Taegu 700422, South Korea

[2] Dongguk Univ, Sch Med, Dept Biochem, Kyungju 780714, South Korea

[3] Kyungpook Natl Univ, Dept Biochem & Cell Biol, Cell & Matrix Res Inst, Sch Med, Taegu 700422, South Korea

[4] Korea Inst Radiol & Med Sci, Radiol & Med Sci Res Ctr, Seoul 139709, South Korea

[5] Kyungpook Natl Univ, Dept Pharmacol, Sch Med, Taegu 700422, South Korea

来源：

CANCER LETTERS | 2010年 / 291卷 / 01期

关键词：

Combination gene therapy; HSV1-tk; shRNA; MDR1; I-131-FIAU imaging; TYPE-1 THYMIDINE KINASE; POSITRON-EMISSION-TOMOGRAPHY; IN-VIVO; RNA INTERFERENCE; HEPATOCELLULAR-CARCINOMA; TRANSGENE EXPRESSION; GANCICLOVIR; CANCER; CELLS; TRANSPORTERS;

D O I：

10.1016/j.canlet.2009.10.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The use of a novel therapeutic vector containing HSV1-thymidine kinase (HSV1-tk) and a short hairpin RNA for the MDR1 gene (shMDR) was proposed previously. We investigated the antitumor effects in an in vivo mouse model of colon cancer and assessed treatment response by serial non-invasive imaging. shMDR-TK expressing (MTKG) tumors for the dual therapy group mice with ganciclovir and doxorubicin showed a decrease in size, while tumors in the single therapy group mice showed a moderate increase (p < 0.05). The I-131-5-iodo-2'-fluoro-2'deoxy-1-beta-D-arabinofuranosyluracil (FIAU) uptake ratio of MTKG-to-parent HCT-15 tumors decreased as treatment progressed for single or dual therapy group mice, while that of the control group mice increased gradually. This study demonstrates the enhanced antitumor effects with combination gene therapy compared with a single therapeutic approach, and provides the potential of therapeutic response monitoring. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

引用

页码：83 / 89

页数：7

共 36 条

[1] Prodrug cancer gene therapy [J].

Altaner, Cestmir .

CANCER LETTERS, 2008, 270 (02) :191-201

[2]

Black ME, 2001, CANCER RES, V61, P3022

[3] In vitro and in vivo enhancement of ganciclovir-mediated bystander cytotoxicity with gemcitabine [J].

Boucher, PD ;

Shewach, DS .

MOLECULAR THERAPY, 2005, 12 (06) :1064-1071

[4] Hydroxyurea significantly enhances tumor growth delay in vivo with herpes simplex virus thymidine kinase/ganciclovir gene therapy [J].

Boucher, PD ;

Ostruszka, LJ ;

Murphy, PJM ;

Shewach, DS .

GENE THERAPY, 2002, 9 (15) :1023-1030

[5]

Deng WP, 2006, J NUCL MED, V47, P877

[6] Non-invasive in vivo imaging with radiolabelled FIAU for monitoring cancer gene therapy using herpes simplex virus type 1 thymidine kinase and ganciclovir [J].

Deng, WP ;

Yang, WK ;

Lai, WF ;

Liu, RS ;

Hwang, JJ ;

Yang, DM ;

Fu, YK ;

Wang, HE .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (01) :99-109

[7]

Dilber MS, 1997, CANCER RES, V57, P1523

[8] Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans [J].

Fire, A ;

Xu, SQ ;

Montgomery, MK ;

Kostas, SA ;

Driver, SE ;

Mello, CC .

NATURE, 1998, 391 (6669) :806-811

[9]

FREEMAN SM, 1993, CANCER RES, V53, P5274

[10] Imaging transgene expression with radionuclide imaging technologies [J].

Gambhir, SS ;

Herschman, HR ;

Cherry, SR ;

Barrio, JR ;

Satyamurthy, N ;

Toyokuni, T ;

Phelps, ME ;

Larson, SM ;

Balatoni, J ;

Finn, R ;

Sadelain, M ;

Tjuvajev, J ;

Blasberg, R .

NEOPLASIA, 2000, 2 (1-2) :118-138

← 1 2 3 4 →